Mind Medicine Analyst Ratings
Mind Medicine Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/04/2023 | 345.86% | EF Hutton | → $21 | Reiterates | Buy → Buy |
| 07/10/2023 | 6.16% | RBC Capital | → $5 | Reiterates | Outperform → Outperform |
| 06/28/2023 | 1492.36% | HC Wainwright & Co. | $75 → $75 | Reiterates | Buy → Buy |
| 06/21/2023 | 6.16% | RBC Capital | → $5 | Reiterates | Outperform → Outperform |
| 06/20/2023 | 345.86% | EF Hutton | → $21 | Reiterates | Buy → Buy |
| 05/18/2023 | 48.62% | Cantor Fitzgerald | → $7 | Reiterates | → Overweight |
| 05/18/2023 | 345.86% | EF Hutton | → $21 | Reiterates | Buy → Buy |
| 05/09/2023 | 1492.36% | HC Wainwright & Co. | → $75 | Reiterates | → Buy |
| 05/05/2023 | 345.86% | EF Hutton | → $21 | Reiterates | → Buy |
| 04/18/2023 | 1492.36% | HC Wainwright & Co. | → $75 | Reiterates | → Buy |
| 04/14/2023 | 367.09% | Oppenheimer | → $22 | Reiterates | → Outperform |
| 04/14/2023 | 345.86% | EF Hutton | → $21 | Reiterates | → Buy |
| 03/16/2023 | 1492.36% | HC Wainwright & Co. | → $75 | Reiterates | → Buy |
| 03/10/2023 | 6.16% | RBC Capital | → $5 | Reiterates | → Outperform |
| 03/10/2023 | 345.86% | EF Hutton | → $21 | Reiterates | → Buy |
| 01/19/2023 | 1492.36% | HC Wainwright & Co. | → $75 | Reiterates | → Buy |
| 12/16/2022 | 345.86% | EF Hutton | → $21 | Initiates Coverage On | → Buy |
| 11/16/2022 | 6.16% | RBC Capital | → $5 | Initiates Coverage On | → Outperform |
| 09/21/2022 | 1492.36% | HC Wainwright & Co. | $5 → $75 | Maintains | Buy |
| 08/26/2022 | -25.69% | Oppenheimer | → $3.5 | Initiates Coverage On | → Outperform |
| 08/16/2022 | 6.16% | HC Wainwright & Co. | $10 → $5 | Maintains | Buy |
| 05/04/2022 | 48.62% | Roth Capital | → $7 | Initiates Coverage On | → Buy |
| 08/05/2021 | 112.31% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 06/28/2021 | 27.39% | Maxim Group | → $6 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/04/2023 | 345.86% | EF Hutton | → 21 美元 | 重申 | 购买 → 购买 |
| 07/10/2023 | 6.16% | 加拿大皇家银行资本 | → 5 美元 | 重申 | 跑赢大盘 → 跑赢大盘 |
| 06/28/2023 | 1492.36% | HC Wainwright & Co. | 75 美元 → 75 美元 | 重申 | 购买 → 购买 |
| 06/21/2023 | 6.16% | 加拿大皇家银行资本 | → 5 美元 | 重申 | 跑赢大盘 → 跑赢大盘 |
| 06/20/2023 | 345.86% | EF Hutton | → 21 美元 | 重申 | 购买 → 购买 |
| 05/18/2023 | 48.62% | 坎托·菲茨杰拉德 | → 7 美元 | 重申 | → 超重 |
| 05/18/2023 | 345.86% | EF Hutton | → 21 美元 | 重申 | 购买 → 购买 |
| 05/09/2023 | 1492.36% | HC Wainwright & Co. | → 75 美元 | 重申 | → 购买 |
| 05/05/2023 | 345.86% | EF Hutton | → 21 美元 | 重申 | → 购买 |
| 04/18/2023 | 1492.36% | HC Wainwright & Co. | → 75 美元 | 重申 | → 购买 |
| 04/14/2023 | 367.09% | 奥本海默 | → 22 美元 | 重申 | → 跑赢大盘 |
| 04/14/2023 | 345.86% | EF Hutton | → 21 美元 | 重申 | → 购买 |
| 03/16/2023 | 1492.36% | HC Wainwright & Co. | → 75 美元 | 重申 | → 购买 |
| 03/10/2023 | 6.16% | 加拿大皇家银行资本 | → 5 美元 | 重申 | → 跑赢大盘 |
| 03/10/2023 | 345.86% | EF Hutton | → 21 美元 | 重申 | → 购买 |
| 01/19/2023 | 1492.36% | HC Wainwright & Co. | → 75 美元 | 重申 | → 购买 |
| 2022 年 12 月 16 日 | 345.86% | EF Hutton | → 21 美元 | 启动覆盖开启 | → 购买 |
| 11/16/2022 | 6.16% | 加拿大皇家银行资本 | → 5 美元 | 启动覆盖开启 | → 跑赢大盘 |
| 09/21/2022 | 1492.36% | HC Wainwright & Co. | 5 美元 → 75 美元 | 维护 | 购买 |
| 2022 年 8 月 26 日 | -25.69% | 奥本海默 | → 3.5 美元 | 启动覆盖开启 | → 跑赢大盘 |
| 08/16/2022 | 6.16% | HC Wainwright & Co. | 10 美元 → 5 美元 | 维护 | 购买 |
| 05/04/2022 | 48.62% | 罗斯资本 | → 7 美元 | 启动覆盖开启 | → 购买 |
| 08/05/2021 | 112.31% | HC Wainwright & Co. | → 10 美元 | 启动覆盖开启 | → 购买 |
| 2021 年 6 月 28 日 | 27.39% | Maxim 集团 | → 6 美元 | 启动覆盖开启 | → 购买 |
What is the target price for Mind Medicine (MNMD)?
心灵医学（MNMD）的目标价格是多少？
The latest price target for Mind Medicine (NASDAQ: MNMD) was reported by EF Hutton on August 4, 2023. The analyst firm set a price target for $21.00 expecting MNMD to rise to within 12 months (a possible 345.86% upside). 21 analyst firms have reported ratings in the last year.
EF Hutton于2023年8月4日公布了Mind Medicine（纳斯达克股票代码：MNMD）的最新目标股价。这家分析公司将目标股价定为21.00美元，预计MNMD将在12个月内升至21.00美元（可能上涨345.86％）。去年有21家分析公司公布了评级。
What is the most recent analyst rating for Mind Medicine (MNMD)?
Mind Medicine（MNMD）的最新分析师评级是多少？
The latest analyst rating for Mind Medicine (NASDAQ: MNMD) was provided by EF Hutton, and Mind Medicine reiterated their buy rating.
Mind Medicine（纳斯达克股票代码：MNMD）的最新分析师评级由EF Hutton提供，Mind Medicine重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Mind Medicine (MNMD)?
Mind Medicine（MNMD）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mind Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mind Medicine was filed on August 4, 2023 so you should expect the next rating to be made available sometime around August 4, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与Mind Medicine的高管和客户交谈以及听取财报电话会议）后得出了股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Mind Medicine的最后一次评级是在2023年8月4日提交的，因此你应该预计下一个评级将在2024年8月4日左右公布。
Is the Analyst Rating Mind Medicine (MNMD) correct?
分析师对 Mind Medicine (MNMD) 的评级正确吗？
While ratings are subjective and will change, the latest Mind Medicine (MNMD) rating was a reiterated with a price target of $0.00 to $21.00. The current price Mind Medicine (MNMD) is trading at is $4.71, which is within the analyst's predicted range.
虽然评级是主观的，会发生变化，但最新的Mind Medicine（MNMD）评级得到了重申，目标股价为0.00美元至21.00美元。Mind Medicine（MNMD）目前的交易价格为4.71美元，在分析师的预测区间内。